Autoimmune diabetes is believed to be mediated primarily by T cells. However, B cells have been implicated in the pathogenesis of the disease in NOD mice. Although preclinical studies have been limited by the absence of anti-CD20 reagents that can induce B cell depletion in mice, a clinical trial using the B cell-depleting anti-CD20 monoclonal antibody rituximab (Rituxan) is underway in type 1 diabetes patients. In this issue of the JCI, Hu et al. describe the generation of transgenic NOD mice that express human CD20 on B cells (see the related article beginning on page 3857). They show that anti-CD20 therapy induces B cell depletion in these mice and offers some level of protection against diabetes. Although many questions remain unanswered, this mouse model represents the first opportunity to evaluate the potential value of rituximab as a novel therapy for autoimmune diabetes.
. Although initial results have been encouraging in clinical settings in which rituximab has been used to date, many basic questions remain unanswered, such as the optimal dose and regimen, whether rituximab should be used in combination with other therapies to obtain the most favorable outcome, the mode of action of rituximab, and its effect on the immune system beyond B cell depletion.
Role of B cells in autoimmune diabetes
The NOD mouse is a well-characterized model of autoimmune diabetes that is believed to exhibit many of the mechanisms underlying the pathogenesis of the human disease (10) , and as such, it is likely instructive in examining the role of B cells in T1D. Mononuclear infiltrates in both NOD mouse and human islets comprise mainly CD4 + and CD8 + T cells, but B cells, NK cells, dendritic cells, and macrophages have been described (10) (11) (12) . The central role of T cells in autoimmune diabetes was demonstrated in the NOD model by the ability of T cells to transfer disease and the protection afforded by immunotherapies targeting T cells (13) (14) (15) (16) ). The precise function of autoreactive B cells has been more difficult to establish (Figure 1 ). Isletspecific autoantibodies targeting major autoantigens such as glutamic acid decarboxylase and insulin can be detected in the serum in NOD mice and in patients and have been an excellent indicator of autoimmunity and predictor of disease in diabetic patients and relatives (17, 18) . However, a direct pathogenic role for autoantibodies is controversial. Greeley et al. reported that maternal autoantibodies are important for the development of disease in NOD mice (19) , but diabetes cannot be transferred by autoantibodies. In NOD mice, the impor-tance of B cells was clearly demonstrated by the dramatic reduction in insulitis and diabetes incidence following B cell depletion using anti-IgM antibodies at birth or in NOD mice genetically deficient in B cells (20) . Evidence from many different studies suggests that B cells function as islet antigen-presenting cells for autoreactive T cells in NOD mice and that autoantibodies expressed on the cell surface improve the capture and presentation of autoantigens (21) (22) (23) (24) . Importantly, early loss of B cells does not eliminate insulitis in NOD mice, suggesting that autoreactive B cells may be essential at late stages of disease to enhance autoreactivity and promote epitope spreading (20, 21) . This finding has significant clinical implications, since B cell-depleting therapies such as rituximab would be most useful in patients newly diagnosed with T1D or islet transplant recipients (25) . Novel mAbs targeting murine CD20 and inducing B cell depletion have been developed recently (26) , and transgenic mice expressing hCD20 in B cells have been generated on the FVB mouse genetic background (27) and now by Hu et al. (1) on the NOD background. Importantly, the extent and tissue variability of B cell depletion following anti-CD20 therapy appears similar in these models, suggesting that they may provide clinically relevant information. Most significantly, Hu et al. showed that anti-CD20 therapy in new-onset diabetic hCD20/NOD mice reversed diabetes in one-third of the treated mice, providing a much-needed experimental rationale for the investigation of rituximab in T1D, especially since clinical trials are already underway (28) . It is unclear why only a third of mice became euglycemic, but the protocol followed by Hu et al., which consisted of waiting six days after diagnosis of diabetes before starting treatment, a time point when most residual islets have been destroyed, could have contributed to the low success rate. Indeed, in another therapeutic setting, we showed that it is critical to target mice with blood glucose lower than 350 mg/dl (29) . Interestingly, in the Hu et al. study, the reversal of hyperglycemia was characterized by variable and generally slow kinetics but long-term effect. This could reflect the presence of two separate processes: a short-term antiinflammatory effect in islets, whose kinetics might depend on the aggressiveness of the autoimmune infiltrate, and a slower induction of regulatory cell population(s) that could induce long-term tolerance.
Mechanism of action of anti-CD20 therapy in NOD mice
Little is known about the mechanisms underlying the efficacy of "normal" B cell depletion after anti-CD20 therapy. In B cell lymphomas, rituximab induces B cell depletion by three major mechanisms: antibodymediated cellular cytotoxicity (ADCC), whose importance is well-established, and complement-dependent cytotoxicity and antibody-triggered apoptosis, which are more controversial, both in animal models and in humans (30) (Figure 1) . Thus, the multiple defects of the innate immune system in NOD mice may diminish the efficacy of anti-CD20 therapy. Indeed, NOD mice have defects in both inhibitory and activating Fc receptors (which are critical for ADCC) as well as complement pathways (31) (32) (33) . Furthermore, NOD mice display defective monocyte/macrophages and NK cell function (34) (35) (36) , which are important for phagocytosis and ADCC and may thus affect B cell depletion following anti-CD20 treatment. In this regard, comparison of anti-CD20 therapy in mouse strains displaying distinct Fc receptor networks and ADCC capabilities may be useful in mimicking the polymorphism of Fc receptors in humans that can affect ADCC and tumor responses to rituximab (37). Hu et al. (1) make the interesting suggestion that, in hCD20/NOD mice, anti-CD20 treatment leads to the generation of Treg and regulatory B cell populations that can control diabetes in an adoptive transfer model (Figure 1 ). We and others have shown the crucial role of CD4 + CD25 + Tregs in the regulation of autoimmune diabetes in NOD mice (38) (39) (40) . Thus, this cell population is likely a critical element in therapeutic settings in achieving long-term active regulation of disease. However, the increase in Foxp3 + Tregs reported by Hu et al. is quite modest, not clearly antigen specific, and it is still unclear whether this cell population offers any protection from diabetes following anti-CD20 therapy. Additionally, Hu et al. suggest that anti-CD20 therapy affects the distribution of B cell subsets after B cell repopulation and leads to an increase in
Figure 1
Anti-CD20 therapy and B cells in autoimmunity. Autoreactive B cells play a role in autoimmune diseases via their production of circulating autoantibodies and/or their role as antigen-presenting cells for autoreactive T cells after the capture of self antigens by cell surface autoantibodies that increase their antigen-presentation capabilities (i). Rituximab and other anti-CD20 mAbs crosslink CD20 on the surface of B cells and induce B cell depletion mainly through ADCC, although complement-dependent cytotoxicity (CDC) and apoptosis have also been implicated (ii). Anti-CD20-mediated B cell depletion prevents interaction with autoreactive T cells (iii) and reduces the amount of circulating autoantibodies (iv), although with much slower kinetics. transitional type 2 B cells that may have a regulatory function, reminiscent of IL-10-producing "regulatory" B cells that could limit the severity of disease in autoimmunity (41) . Although the current clinical data do not mention the occurrence of autoimmunity following rituximab treatment in lymphoma patients, the elimination of such regulatory B cells may be of concern in B cell-depleting therapies, as demonstrated by a recent case report describing the exacerbation of ulcerative colitis associated with decreased local IL-10 production in one patient following rituximab treatment (42) . In contrast, the possibility that rituximab may favor the development of regulatory B cells in autoimmune diseases is quite interesting and warrants further investigation. Finally, in autoimmune diseases involving autoreactive T and B cells such as T1D, it may be worth considering combination immunotherapies that target both arms of the response, such as combining rituximab with Fc receptor-nonbinding anti-CD3 or Thymoglobulin (Genzyme Corp.) (16, 43) . Indeed, Fc receptor-nonbinding anti-CD3 and Thymoglobulin (antithymocyte globulin) are T cell-targeting therapies believed to function primarily by altering T cell function. The effects of these drugs involve a combination of T cell depletion and the generation of regulatory cell populations such as Tregs (44, 45) . Both drugs have been shown to reverse diabetes in the NOD mouse model (16, 43) . Importantly, Fc receptor-nonbinding anti-CD3 has generated encouraging data in experimental trials of T1D patients, and both drugs are currently in clinical trials in T1D (46, 47) . Thus, a combination of rituximab and T cell-targeting therapies are being tested in animal models and humans, as they may offer a more comprehensive approach to T1D therapy by eliminating autoreactive T and B cells that cooperate to induce disease and generating both Treg and regulatory B cell populations that may contribute to long-term remission and maintenance of tolerance (1, 44) . However, safety is a key component in designing immunotherapies for T1D, since it often begins in young children, and one has to be careful not to trade off the imperfect management of diabetes and its complications with insulin for long-term and generalized immunosuppression.
The development of chronic allograft rejection is based on the hypothesis that cumulative, time-dependent tissue injury eventually leads to a fibrotic response. In this issue of the JCI, Babu and colleagues found that alloimmune-mediated microvascular loss precedes tissue damage in murine orthotopic tracheal allografts (see the related article beginning on page 3774). The concept that injury to the endothelium may precede airway fibrosis suggests that interventions to maintain vascular integrity may be important, especially in the case of lung transplantation. Further, for all solid organ allografts, it is possible that the key to long-term allograft survival is physiological vascular repair at early times following transplantation.
Nonstandard abbreviations used: BOS, bronchiolitis obliterans syndrome.
